Diltiazem Contraindication in Heart Failure

Guideline-Based Contraindication

The European Society of Cardiology recommends that calcium-channel blockers, including diltiazem, should be discontinued unless absolutely necessary in patients with symptomatic heart failure with reduced ejection fraction, due to their negative inotropic effect, with a Class III recommendation (harm) 1, 2
The American Heart Association recommends that nondihydropyridine calcium channel blockers, including diltiazem, should be avoided in patients with heart failure and hypertension, with a Class III recommendation (harm) 3

The European Society of Cardiology recommends beta-blockers as first-line agents for rate control in heart failure patients with atrial fibrillation, with evidence-based agents like carvedilol, bisoprolol, or metoprolol succinate 1

In hypertrophic cardiomyopathy patients who do not tolerate verapamil or in whom verapamil is contraindicated, diltiazem may be considered, with a Class IIb recommendation 4
If diltiazem must be used in the acute setting for rapid rate control, monitor closely for hypotension, bradycardia, increased oxygen requirements, and need for inotropic support, and avoid combination with beta-blockers due to additive negative effects on cardiac conduction 1, 2

The European Society of Cardiology (ESC) guidelines explicitly state that diltiazem is not recommended in patients with heart failure with reduced ejection fraction (HFrEF) due to its negative inotropic effects, with a Class III recommendation and Level C evidence 5
Diltiazem and verapamil-type calcium antagonists are specifically contraindicated in heart failure due to systolic dysfunction, as stated by the European Society of Cardiology 6, 7
The ESC guidelines classify diltiazem among "treatments that may cause harm in patients with symptomatic heart failure with reduced ejection fraction" 8

Beta-blockers are preferred over calcium channel blockers for rate control in heart failure patients, according to the European Society of Cardiology 9
For patients with atrial fibrillation and heart failure, the recommended rate control agents include beta-blockers (first-line), digoxin (can be used alone or in combination with beta-blockers), and amiodarone (for rhythm control in severe heart failure), as recommended by the European Society of Cardiology 9

Routine use of calcium‑channel blockers in patients with heart‑failure with reduced ejection fraction (HFrEF) is discouraged because they exert negative inotropic effects, provide no survival benefit, and may worsen clinical outcomes. 10

First‑generation agents (nifedipine, verapamil, diltiazem) directly depress left‑ventricular contractility and have demonstrated either no clinical benefit or worse outcomes in multiple clinical trials. 10
Second‑generation dihydropyridines (amlodipine, felodipine), despite greater vascular selectivity, have failed to show any functional improvement or survival advantage in HFrEF patients. 10

Verapamil and diltiazem should be avoided in patients with pulmonary edema or severe left‑ventricular dysfunction because of their pronounced negative inotropic effects and the added risk of atrioventricular and sinus‑node suppression. 11

Immediate‑release nifedipine must be completely avoided in HFrEF, as it is associated with increased mortality, especially when not combined with beta‑blockade. 11

Amlodipine has demonstrated neutral effects on morbidity and mortality in large randomized trials, offering no functional or survival benefit for HFrEF patients. 10
Amlodipine may be used only to manage co‑existing hypertension or ischemic heart disease in HFrEF patients and should never be employed as primary heart‑failure therapy. 10

In heart‑failure with preserved ejection fraction (HFpEF), calcium‑channel blockers can be employed for blood‑pressure control, but current evidence does not show a reduction in HF‑specific morbidity or mortality. 10